A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
Albuminuria
Cardiovascular Outcomes
Kidney
Kidney Outcomes
Risk Factor
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
22 08 2022
22 08 2022
Historique:
received:
29
03
2022
accepted:
14
06
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
25
8
2022
Statut:
epublish
Résumé
The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way of assessing risk. 9115 of 9901 Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) participants with both an ACR and eGFR at baseline were included in this post hoc epidemiologic analysis. The hazard of higher baseline levels of 1/eGFR and natural log transformed ACR (calculated as ln [ACR × 100] to eliminate negative values) and their interaction for incident major adverse cardiovascular events (MACE), kidney outcomes, and deaths was estimated. The hazard of the geometric mean of these two baseline measures (the kidney disease index or KDI) was also assessed. A non-linear relationship was observed between 1/eGFR and all three outcomes, and between ln [ACR × 100] and the kidney outcome. There was also a negative interaction between these two risk factors with respect to MACE and death. Conversely, a linear relationship was noted between the KDI and all three outcomes. People in the highest KDI fifth experienced the highest incidence of MACE, death, and the kidney outcome (4.43, 4.56, and 5.55/100 person-years respectively). C statistics for the KDI were similar to those for eGFR and albuminuria. The KDI combines the baseline eGFR and ACR into a novel composite risk factor that has a simple linear relationship with incident serious outcomes in people with diabetes and additional CV risk factors. Trial Registration clinicaltrials.gov NCT01394952.
Sections du résumé
BACKGROUND
The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way of assessing risk.
METHODS
9115 of 9901 Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) participants with both an ACR and eGFR at baseline were included in this post hoc epidemiologic analysis. The hazard of higher baseline levels of 1/eGFR and natural log transformed ACR (calculated as ln [ACR × 100] to eliminate negative values) and their interaction for incident major adverse cardiovascular events (MACE), kidney outcomes, and deaths was estimated. The hazard of the geometric mean of these two baseline measures (the kidney disease index or KDI) was also assessed.
RESULTS
A non-linear relationship was observed between 1/eGFR and all three outcomes, and between ln [ACR × 100] and the kidney outcome. There was also a negative interaction between these two risk factors with respect to MACE and death. Conversely, a linear relationship was noted between the KDI and all three outcomes. People in the highest KDI fifth experienced the highest incidence of MACE, death, and the kidney outcome (4.43, 4.56, and 5.55/100 person-years respectively). C statistics for the KDI were similar to those for eGFR and albuminuria.
CONCLUSIONS
The KDI combines the baseline eGFR and ACR into a novel composite risk factor that has a simple linear relationship with incident serious outcomes in people with diabetes and additional CV risk factors. Trial Registration clinicaltrials.gov NCT01394952.
Identifiants
pubmed: 35996147
doi: 10.1186/s12933-022-01594-6
pii: 10.1186/s12933-022-01594-6
pmc: PMC9396793
doi:
Substances chimiques
Albumins
0
Creatinine
AYI8EX34EU
Banques de données
ClinicalTrials.gov
['NCT01394952']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
158Informations de copyright
© 2022. The Author(s).
Références
Am J Nephrol. 2015;41(4-5):409-17
pubmed: 26139323
Kidney Int. 2011 Jun;79(12):1341-52
pubmed: 21307840
N Engl J Med. 2012 Jul 26;367(4):319-28
pubmed: 22686416
Adv Ther. 2021 Jan;38(1):180-200
pubmed: 33231861
Eur J Prev Cardiol. 2015 Aug;22(8):1018-26
pubmed: 24857889
Diabetes Obes Metab. 2019 Jun;21(6):1299-1304
pubmed: 30714309
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
Diabetologia. 2014 Jul;57(7):1325-31
pubmed: 24771090
JAMA. 2012 Dec 12;308(22):2349-60
pubmed: 23111824
Diabetes Care. 2022 Jan 1;45(Suppl 1):S46-S59
pubmed: 34964869
Diabetes Care. 2021 May;44(5):e85-e86
pubmed: 33632725
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
BMJ. 2021 Sep 28;374:n2134
pubmed: 34583929
Diabetes Obes Metab. 2018 Jan;20(1):42-49
pubmed: 28573765
Nephrol Dial Transplant. 2012 Jun;27(6):2269-74
pubmed: 22090446
JAMA. 2019 Dec 3;322(21):2104-2114
pubmed: 31703124
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602